Backbone hydrolysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised and often hygroscopic |
| Solubility class | Freely soluble in water | Poor solubility in non-polar solvents |
| Typical storage temperature | -20 degrees Celsius or colder | Sealed, desiccated, protected from light |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Establishes purity and confirms mass |
| Common salt form | Trifluoroacetate or acetate | Counterion reported alongside purity values |
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
traveller's joy, a name invented for the sole British native, C. vitalba, by the herbalist John Gerard (1545–1612); virgin's bower for C. terniflora, C. virginiana, and C. viticella; old man's beard, applied to several with prominent seedheads; leather flower for those with fleshy petals; or vase vine for the North American Clematis viorna.
The LLNL chemistry, materials, and life science research focuses on chemical engineering, nuclear chemistry, materials science, and biology and bio-nanotechnology. Physics thrust areas include condensed matter and high-pressure physics, optical science and high energy density physics, medical physics and biophysics, and nuclear, particle and accelerator physics. In the area of energy and environmental science, Livermore's emphasis is on carbon and climate, energy, water and the environment, and the national nuclear waste repository. The LLNL engineering activities include micro- and nanotechnology, lasers and optics, biotechnology, precision engineering, nondestructive characterization, modeling and simulation, systems and decision science, and sensors, imaging and communications. LLNL is a computing organization with capabilities in computer science, software engineering, data science, modeling and simulation, information technology, and cyber security. Lawrence Livermore National Laboratory has worked out several energy technologies in the field of coal gasification, shale oil extraction, geothermal energy, advanced battery research, solar energy, and fusion energy. Main oil shale processing technologies worked out by the Lawrence Livermore National Laboratory are LLNL HRS (hot-recycled-solid), LLNL RISE (in situ extraction technology) and LLNL radiofrequency technologies.
Because of the activity of manufactured 60Co sources, their radioactivity can present a severe hazard to humans, and can cause death (potentially in less than an hour from acute exposure). After entering a living mammal (such as a human), assuming that the subject does not die shortly after exposure (as may happen in acute exposure incidents), some of the 60Co is excreted in feces. The rest is taken up by tissues, mainly the liver, kidneys, and bones, where the prolonged exposure to gamma radiation can cause cancer. Over time, the absorbed cobalt is eliminated in urine.
Sources: en.wikipedia.org
The Bowery Mural is an outdoor exhibition space located on the corner of Houston Street and the Bowery, on a wall owned by Goldman Properties since 1984. Real estate developer Tony Goldman began the project with Jeffery Deitch and Deitch Projects in 2008. Goldman's goal was to use this wall to present the top contemporary artists from around the world, with an emphasis on artists who work on the streets. Seasonal murals have appeared on the wall curated and organized in collaboration with The Hole, NYC, an art gallery in SoHo run by former Deitch Projects directors Kathy Grayson and Meghan Coleman. The mural series was initiated from March to December 2008 with a tribute to Keith Haring’s noted 1982 Bowery mural. This was followed by a mural by the Brazilian twin-brother duo Os Gêmeos, which they dedicated to artist Dash Snow, who had recently died from a drug overdose; this was presented from July 2009 to March 2010. The next mural, by Shepard Fairey, was on exhibit from April through August 2010, and was followed by a mural by Barry McGee which celebrated the role of graffiti tagging in the history of New York City street art; it was on display from August to November 2010. This was followed by a tribute to Dash Snow by Irak, which ran from November 24–26, 2010. Other artists to have murals presented include the twins How & Nosm (2012), Crash (2013), Martha Cooper (2013), Revok and Pose (2013), Swoon (2014), and Maya Hayuk.
The three substrates of this enzyme are 4-formylbenzenesulfonic acid, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are 4-sulfobenzoic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 4-formylbenzenesulfonate:NAD+ oxidoreductase. This enzyme participates in 2,4-dichlorobenzoate degradation.
== Theory of operation == The concept behind the Bradbury–Nielsen shutter is to apply a high frequency voltage in a 180° out-of-phase manner to alternate wires in a grid which is orthogonal to the path of the ion beam. This results in charged particles only passing directly through the shutter at certain times in the voltage phase (φ=nπ/2), when the potential difference between the grid wires is zero. At other times the ion beam is deflected to some angle by the potential difference between the neighboring wires. This deflection is divergent with ions that pass through alternate slits being deflected in opposite directions. The maximum deflection angle can be calculated by tan α = k Vp / V0 where α is the deflection angle, k is a deflection constant, Vp is the wire voltage (+Vp on one wire set and -Vp on the other), and V0 is the ion acceleration voltage in eV. The deflection constant k can be calculated by k = π / 2ln[cot(πR/2d)] where R is the wire radius and d is the wire spacing.
=== Announcement and delay === Valve announced Half-Life 2 at E3 2003, with demonstrations of the characters, animation and physics. The reaction was positive, and the game won the E3 Game of the Show award. Newell also announced a release date of September 30, 2003, hoping this would motivate the team. They worked long hours to meet the deadline, but by July it was clear they would miss it. Rumors spread of a delay. On September 23, Valve released a statement targeting a release for the holiday season, leading to fan backlash. Newell had been hesitant to announce a delay without a new release date. He said later: "We were paralyzed. We knew we weren't going to make the date we promised, and that was going to be a huge fiasco and really embarrassing. But we didn't have a new date to give people either." The graphics card manufacturer ATI had arranged a promotional event on Alcatraz Island to coincide with the planned release of Half-Life 2. Unable to pull out of the event, Newell gave a prepared speech, demonstrated the Source engine, and left without addressing questions.
Sources: en.wikipedia.org
In December 2024, the Auditor General of Ontario questioned the financial prudence of the relocation. Contrary to the Ford government's business plan analysis, which projected $257 million in savings over 50 years, the AG found that relocation costs have already exceeded the anticipated savings, reaching approximately $400 million.In May 2025, the Canadian Architect magazine reported that draft versions of the structural engineering report by Rimkus Consulting that the Ontario government had relied on in deciding to close the centre, had originally recommended routine repairs and not closure, up until May 2024. This revelation was added to earlier reporting from Global News that Infrastructure Ontario had been in frequent communication with Rimkus in the leadup to the public release of the report in June 2024, and led the magazine to conclude that the language describing the consequences of not doing the routine repair that was later used to justify the closure had been inserted after political pressure. In February 2026, Ford unveiled the designs of the new building and announced that a contract had been awarded for its construction. It will cost an estimated $1 billion and will be smaller than the original facility, with a footprint of about 400,000 square feet. The Centre would also incorporate the Ontario Place pods as exhibit space and the Cinesphere. The proposed move has been controversial.
"Hem. Marker study, ADULTS over 16 years;Asc";Hem. Marker examination, ADULTS over 16 years, Ascites fluid;Hematology marker laboratory "Erythrocytes;Asc";"Asc-Erythrocytes; count";Clinical Biochemistry Laboratory "Erythrocytes;Asc";"Asc-Erythrocytes; numberk";, Clinical Biochemistry Laboratory "Leukocytes(mononuclear);Asc";"Asc-Leukocytes(mononuclear); count";Clinical Biochemistry Laboratory "Leukocytes(polynucleus);Asc";"Asc-Leukocytes(polynucleus); count";Clinical Biochemistry Laboratory "Nucleated cells;Asc";"Asc-Nucleated cells; count";Clinical Biochemistry Laboratory "Nucleated cells;Asc";"Asc-Nucleated cells; numberk";Clinical Biochemistry Laboratory "Carbamide;Asc";"Asc-Carbamide; substancek";Clinical Biochemistry Laboratory "Calcium;Asc";"Asc-Calcium(II); substance c.";Clinical Biochemistry Laboratory "Phosphate;Asc";"Asc-Phosphate(P; inorganic); substance";Clinical Biochemistry Laboratory "Triglyceride;Asc";"Asc-Triglyceride; substance";Clinical Biochemistry Laboratory "Bilirubins;Asc";Asc-Bilirubins, substance;Clinical Biochemistry Laboratory "Albumin;Asc";"Asc-Albumin; bulk";Clinical Biochemistry Laboratory "Protein;Asc";"Asc-Protein; mass spec.";Clinical Biochemistry Laboratory "Amylase, pancreatic type;Asc";"Asc-Amylase, pancreatic type;cat.k.";Clinical Biochemistry Laboratory "Lactate dehydro ase;Asc";"Asc-Lactate dehydro ase;.";Clinical Biochemistry Laboratory "Cholesterol;Asc";"Asc-Cholesterol+ester; substance c.";Clinical Biochemistry Laboratory "Ascites group;Asc";"A Alternative list for Ascites fluid analyses: The following analyses (Normal Order Name; Designation in the laboratory; Laboratory) can be performed on the sample material Ascites fluid.
== History == Nalbuphine was first synthesized in 1965 and was introduced for medical use in the United States in 1979. In the search for opioid analgesics with less abuse potential than pure MOR agonist opioids, a number of semisynthetic opioids were developed. These substances are referred to as mixed agonist–antagonists analgesics. Nalbuphine belongs to this group of substances. The mixed agonists-antagonists drug class exerts their analgesic actions by agonistic activity at the KOR. While all drugs in this class possess MOR antagonistic activity leading to less abuse potential, nalbuphine is the only approved drug in the mixed agonist–antagonist class listed in terms of its pharmacological actions and selectivities on opioid receptors as a MOR partial agonist or antagonist as well as a KOR agonist (Gustein et al. 2001). Nubain was approved for marketing in the United States in 1978 and remains as the only opioid analgesic of this type (marketed in the U.S.) not controlled under the Controlled Substances Act (CSA). When the Controlled Substances Act (CSA) was enacted in 1971, nalbuphine was placed in schedule II. Endo Laboratories, Inc. subsequently petitioned the DEA to exclude nalbuphine from all schedules of the CSA in 1973. After receiving a medical and scientific review and a scheduling recommendation from the Department of Health, Education and Welfare, forerunner to the Department of Health and Human Services, nalbuphine was removed from schedule II of the CSA in 1976. Presently, nalbuphine is not a controlled substance under the CSA.
Sources: en.wikipedia.org
Sealed lyophilised powder is normally kept at minus twenty degrees Celsius or below, away from light and moisture. Vials are allowed to reach room temperature before opening to limit condensation. Repeated warming and cooling of the same vial is discouraged.
Reversed-phase HPLC establishes purity and separation from related peptides, and mass spectrometry confirms the molecular mass. Amino acid analysis can verify residue composition. No single method proves identity on its own, so the results are read together.
Yes. Residual trifluoroacetate or acetate from purification adds mass and can shift the value obtained by certain assays. Purity figures are therefore meaningful only when the counterion form is stated. Reporting both peptide content and salt form gives a clearer picture.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.